US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.62

-1.5742-3.48%

Volume:2K

Turnover:108.32K

Market Cap:32.72M

PE:- -

High:43.76

Open:43.66

Low:43.62

Close:45.20

52wk High:45.20

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.19

T/O Rate:0.33%

Dividend:0.14

Dividend Rate:0.33%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ligand initiated with an Overweight at Barclays

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Natera, Inc. : RBC Raises Target Price to $460 from $350

THOMSON REUTERS

Wainwright sees upside in Ligand after new CAR-T investment in AvenCell

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell

MT Newswires Live

Ligand and Avencell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

THOMSON REUTERS

Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing

THOMSON REUTERS

Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

Editas slips amid pressure on gene-editing sector after Anthropic update

Ligand Pharmaceuticals Incorporated : Citigroup Raises Target Price to $397 from $390

THOMSON REUTERS

Ligand price target raised to $397 from $390 at Citi

Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement

New precision medicine venture gives Syngenis added firepower

The West Australian

Ligand Pharmaceuticals Joins Signet-Led Financing Round in Primrose Bio

Sydnexis : Agreement Includes $23 Mln Upfront Payment

THOMSON REUTERS

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea

THOMSON REUTERS

Press Release: Primrose Bio(R) Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Natera’s Signatera Wins Japan PMDA Approval as Companion Diagnostic in Muscle-Invasive Bladder Cancer

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/HELX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.621,"timestamp":1791305368749,"preClose":45.1952,"halted":0,"volume":2477,"delay":0,"changeRate":-0.03483113250964699,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Trading","change":-1.5742,"latestTime":"10-06 12:55:40 EDT","open":43.66,"high":43.76,"low":43.621,"amount":108320.82005,"amplitude":0.003076,"askPrice":43.33,"askSize":600,"bidPrice":43.17,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791316800000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":45.1952,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003313,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.79,"preClose":45.1952,"latestTime":"16:10 EDT","volume":7,"amount":313.556,"timestamp":1791231005654,"change":-1.4052,"changeRate":-0.031092,"amplitude":0},"volumeRatio":0.185205,"impliedVol":0.1238,"impliedVolPercentile":0.5378},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.185205,"shares":750000,"dividePrice":0.1445,"high":43.76,"amplitude":0.003076,"preClose":45.1952,"low":43.621,"week52Low":31.44,"pbRate":"--","week52High":45.1952,"institutionHeld":0,"latestPrice":43.621,"eps":0,"divideRate":0.003313,"volume":2477,"delay":0,"ttmEps":0,"open":43.66,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.4008,"twentyDayClose":41.6426,"sixtyDayClose":39.7282},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670590449","title":"Ligand initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2670590449","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670590449?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:45","pubTimestamp":1790325913,"startTime":"0","endTime":"0","summary":"Barclays analyst Glen Santangelo initiated coverage of Ligand (LGND) with an Overweight rating and $345 price target The firm says Ligand is “diffe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","LGND","BK4139","IE0009354923.USD","BK4007","HELX","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPC","AEE","BNY","KMX","TRUC","PYPL","SO","GPOR","CRL","COST","TRUN","GEN","HELX","GRAL","ACAD","NTRA","CDNL","XLP","ALM","CF","CVX","UGE","OKTA","DRI","DMRA","CGEM","XOM","AXGN","CNK","LMRI","P","EMR","UPW","GDDY","FFBC","INFQ","GXPE","CRK","FUL","OILT","KNF","CMCSA","ANDG","STZ","FSTA","META","OBK","MMM","AKAM","CPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412156","title":"Natera, Inc. : RBC Raises Target Price to $460 from $350","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412156?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:19","pubTimestamp":1790306366,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H007:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1988902786.USD","LU2065169927.USD","LU2264538146.SGD","LU0053671581.USD","LU0012050646.USD","LU2065171311.SGD","HELX","LU0963586101.USD","GNOM","LU2324357040.USD","LU0345770308.USD","BK4139","LU0106261612.USD","LU2065170008.USD","LU1064131342.USD","LU0345770993.USD","LU2065171402.SGD","NTRA","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669491495","title":"Wainwright sees upside in Ligand after new CAR-T investment in AvenCell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669491495","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669491495?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:10","pubTimestamp":1790262611,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis notes that this morning, Ligand (LGND) announced an up to $47M investment into AvenCell Therapeutics for d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-sees-upside-in-ligand-after-new-car-t-investment-in-avencell-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-sees-upside-in-ligand-after-new-car-t-investment-in-avencell-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","IE0009354923.USD","LU1559883803.SGD","HELX","BK4139","BK4007","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU2468319806.SGD","LU1670627923.USD","LU2089984988.USD","GRAL","TMED","SG9999002232.USD","SGXZ41872573.SGD","LU0868494617.USD","LU2324357040.USD","SGXZ23171101.USD","BK4585","LU1721429741.USD","LU1721429402.USD","BK4581","GH","HELX","IE0002141913.USD","GNMX","PJP","IE00B4R5TH58.HKD","LU1061106388.HKD","LU0289739699.SGD","LU1691799644.USD","IE00B2B36J28.USD","LFSC","BK4196","FFOX","LU0122379950.USD","PTH","LU0320765489.SGD","LABU","LU0889565916.HKD","LU2112291526.USD","BK4082","LU1989763690.USD","BK4139","BK4535","LU0211331839.USD","ABT","IHI","EKG","SG9999004303.SGD","LU0882574055.USD","BK4588","LU2237957811.SGD","BK4568","GNOM","SG9999002224.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669902467","title":"Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669902467","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669902467?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:35","pubTimestamp":1790249721,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals  said Thursday it agreed to provide up to $47 million to AvenCell Therapeutics to support development of its cell therapy programs.Ligand said it will provide up to $41 million in exchange for a mid-single-digit to low-double-digit royalty on worldwide annual net sales of AvenCell's current and future pipeline.The funding will be provided in four tranches, with later payments tied to clinical milestones and other conditions, it added.Ligand said it also committed up to $6 million to AvenCell's Series C financing.AvenCell is developing therapies in a phase 1 trial to treat cancers, Ligand added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0566484027.USD","IE0009354923.USD","LU1559883803.SGD","HELX","BK4139","BK4007","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669846230","title":"Ligand and Avencell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669846230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669846230?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SZPQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","HELX","BK4139","LU0566484027.USD","BK4007","LU1559883803.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462584","title":"Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462584?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SZPQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","HELX","LU1559883803.SGD","IE0009354923.USD","BK4007","BK4139","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462637","title":"Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462637","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462637?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","HELX","03160","BK4585","LU0566484027.USD","IE0009354923.USD","BK4604","LGND","R","BK4539","BK4588","BK4555","BK4007","BK4232","LU1559883803.SGD","BK4230","CAR","LENZ","TM","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435367","title":"Editas slips amid pressure on gene-editing sector after Anthropic update","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435367?lang=en_us&edition=fundamental","pubTime":"2026-09-24 02:55","pubTimestamp":1790189712,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. An...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","LU1861558580.USD","EDIT","GNMX","BK4585","HELX","IDNA","WDNA","BK4139","CRSP","BK4556","SYNB","ARKG","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669558102","title":"Ligand Pharmaceuticals Incorporated : Citigroup Raises Target Price to $397 from $390","url":"https://stock-news.laohu8.com/highlight/detail?id=2669558102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669558102?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:50","pubTimestamp":1790157016,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0CR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1559883803.SGD","BK4139","IE0009354923.USD","HELX","LU0566484027.USD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669024781","title":"Ligand price target raised to $397 from $390 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669024781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669024781?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:45","pubTimestamp":1790156708,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Ligand (LGND) to $397 from $390 and keeps a Buy rating on the shares. The firm cites the company’s acquisiti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-397-from-390-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-397-from-390-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","HELX","LGND","BK4139","IE0009354923.USD","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669861121","title":"Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669861121","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669861121?lang=en_us&edition=fundamental","pubTime":"2026-09-23 02:15","pubTimestamp":1790100924,"startTime":"0","endTime":"0","summary":"• Natera's clinical milestones and Signatera validation bolstered investor confidence.\n• Management highlighted accelerating test adoption and long-term gross margin expansion.\n• Wall Street sentiment remains favorable with multiple analysts issuing buy ratings.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262181061-market-movers-ntra-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065731478.USD","LU0106261612.USD","LU0012050646.USD","LU2065171402.SGD","LU2324357040.USD","LU2065170008.USD","NTRA","HELX","BK4139","LU0345770308.USD","LU0963586101.USD","LU2264538146.SGD","LU1064131342.USD","LU2065169927.USD","LU1988902786.USD","GNOM","LU0053671581.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["HTEC","XT","OZR.AU","OZF.AU","IOZ.AU","BBOZ.AU","E200.AU","TMAT","ADHD","WDNA","BK4588","GIVE.AU","ZYAU.AU","STW.AU","SYNB","IISV.AU","SLF.AU","LFSC","MEDX","GNOM","VAP.AU","IMLC.AU","IBB","EIGA.AU","XJO.AU","BK4585","BMED","DACE.AU","FDIF","GEAR.AU","IDNA","HELX","IIGF.AU","GDOC","JDOC","QRE.AU","XAO.AU","VAS.AU","PBE","BEAR.AU","EES","GNMX","QFN.AU","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142256","title":"Ligand Pharmaceuticals Joins Signet-Led Financing Round in Primrose Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142256","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142256?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082279,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals joins Signet-led financing round in Primrose BioPrimrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from Ligand Pharmaceutic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3qpSgQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","HELX","LGND","IE0009354923.USD","LU0566484027.USD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669314243","title":"Sydnexis : Agreement Includes $23 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669314243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669314243?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0DF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGND","LU1559883803.SGD","BK4007","IE0009354923.USD","LU0566484027.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142436","title":"Sydnexis Announces Royalty Agreement with Ligand for Ryjunea","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142436?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082140,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","HELX","LGND","IE0009354923.USD","BK4007","BK4139","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669421791","title":"Press Release: Primrose Bio(R) Raises Significant Growth Capital Investment Led by Signet Healthcare Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2669421791","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669421791?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. , a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners , with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated , LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors.The proceeds will help Primrose continue to expand the reach and capabilities of its differentiated technology portfolio:-- Pfenex Expression Technology , a scalable microbial. expression platform for efficient, high-yield production of complex,-- Prima RNApols, proprietary RNA polymerases for consistent, scalable,-- PeliCRM197, a validated carrier protein used in multiple approved","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","BK4585","XBI","XLV","BK4588","BK4137","R","HELX","BK4232","LGND","HCSG","LU0029874061.USD","LU0128526141.USD","LABU","BK4581","BK4022","BK4139","IE0009354923.USD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414421","title":"Natera’s Signatera Wins Japan PMDA Approval as Companion Diagnostic in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414421","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414421?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:04","pubTimestamp":1790078642,"startTime":"0","endTime":"0","summary":"Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancerNatera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladd","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8Klqhw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0012050646.USD","LU0963586101.USD","NTRA","LU2065170008.USD","LU2065169927.USD","LU1988902786.USD","GNOM","LU1064131342.USD","LU2065731478.USD","LU0053671581.USD","HELX","LU0345770308.USD","LU2264538146.SGD","LU2065171402.SGD","LU2324357040.USD","LU0106261612.USD","LU0345770993.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669600141","title":"Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669600141","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669600141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA93GLLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131342.USD","LU0963586101.USD","LU2264538146.SGD","LU2324357040.USD","NTRA","LU0345770308.USD","GNOM","LU0106261612.USD","LU0012050646.USD","LU0345770993.USD","LU2065170008.USD","LU0053671581.USD","LU2065171402.SGD","HELX","LU1988902786.USD","LU2065171311.SGD","LU2065731478.USD","BK4139","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}